Among the four subtypes of non-Hodgkin’s lymphoma (NHL), diffuse large B-cell lymphoma DLBCL is the most common in China. Rituximab (Roche’s MabThera, biosimilars) continues to dominate China…
Bladder cancer is one of the most commonly diagnosed cancers and a substantial cause of cancer-related deaths in China. The bladder cancer market is set to enter a competitive and dynamic period of…
DRG provides key insights on biosimilars companies’ development strategies and assesses how innovator companies can defend their biologic portfolios.
Pulmonary hypertension (PH) is a devastating disease with high levels of morbidity and mortality and no cure. Despite the disease’s rarity, the potential commercial opportunities for drugs…
MARKET OUTLOOK Dyslipidemia is an important modifiable risk factor for CV disease and is primarily managed with statin therapy. Based on the positive CVOT data for certain nonstatin therapies,…
Pulmonary hypertension (PH) is a devastating disease, for which there is no cure. Despite the rarity of the disease, the potential commercial rewards from drugs approved for it are considerable,…
The development and commercialization of biosimilars require a significant investment in capital, resources, and time. Biosimilar developers must ensure that they are equipped with the necessary…
The biosimilars space is expected to become increasingly competitive as reference brand companies try to retain market share in the face of their product’s dwindling patent life and biosimilar…
Developing a biosimilar requires considerable investment and expertise. In order to maximize potential commercial return, biosimilar developers must adopt clear and effective strategies that…
Biosimilars are potentially disruptive to the pharmaceutical industry; the biosimilars sector not only allows extremely lucrative commercial opportunities for biosimilar companies but also poses an…
Emerging markets present great opportunities but also numerous challenges to multinational pharmaceutical corporations (MNCs). With large and growing populations, robust projected market growth,…
The Chinese market for hepatocellular carcinoma (HCC) therapies represents an increasingly lucrative space for many pharmaceutical companies. Although the high prices demanded by targeted brands…
In order to maximize potential commercial return, biosimilar developers must adopt clear and effective strategies that leverage their internal capability and potentially capture the expertise of…